Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Iastrebner, Marcelo, Castro, Joaquín, García Espina, Edgardo, Lettieri, Carolina, Payaslian, Silvio, Cuesta, María Celia, Gutiérrez Fernández, Pablo, Mandrile, Araceli, Contreras, Angela Paola, Gervasoni, Sebastián, Verde, Gabriel, Galetti, Cayetano, Minoldo, Estefanía, Caruso, Vanesa
Formato: Artículo revista
Lenguaje:Inglés
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/32800
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
Descripción
Sumario:Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment.

Ejemplares similares